Bayer (OTCMKTS:BAYRY) Lifted to Buy at Bank of America

Share on StockTwits

Bayer (OTCMKTS:BAYRY) was upgraded by Bank of America from a “neutral” rating to a “buy” rating in a research report issued to clients and investors on Friday, Briefing.com Automated Import reports.

A number of other analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of Bayer from a “hold” rating to a “sell” rating and set a $17.00 price target on the stock. in a report on Wednesday, August 7th. ValuEngine upgraded shares of Bayer from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $17.00.

OTCMKTS BAYRY traded up $0.26 on Friday, reaching $17.81. The company had a trading volume of 37,348 shares, compared to its average volume of 618,755. The company has a quick ratio of 0.92, a current ratio of 1.37 and a debt-to-equity ratio of 0.79. The stock has a market capitalization of $65.46 billion, a PE ratio of 10.18, a price-to-earnings-growth ratio of 0.97 and a beta of 1.09. The firm’s 50 day moving average price is $16.93 and its 200 day moving average price is $17.16. Bayer has a 12 month low of $14.61 and a 12 month high of $24.31.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Story: Convertible Shares

Analyst Recommendations for Bayer (OTCMKTS:BAYRY)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Merit Medical Systems  PT Lowered to $40.00
Merit Medical Systems PT Lowered to $40.00
Gaming and Leisure Properties  Rating Increased to Hold at Zacks Investment Research
Gaming and Leisure Properties Rating Increased to Hold at Zacks Investment Research
Red River Bancshares  Stock Rating Lowered by Zacks Investment Research
Red River Bancshares Stock Rating Lowered by Zacks Investment Research
Ritter Pharmaceuticals  Downgraded to “Sell” at ValuEngine
Ritter Pharmaceuticals Downgraded to “Sell” at ValuEngine
Maxim Group Reaffirms “Hold” Rating for NXT-ID
Maxim Group Reaffirms “Hold” Rating for NXT-ID
BlackRock TCP Capital  Upgraded at BidaskClub
BlackRock TCP Capital Upgraded at BidaskClub


 
© 2006-2019 Zolmax.